GlyNAC pairs two inexpensive amino acids that rebuild glutathione, an internal antioxidant that declines with age. Its clearest effect is restoring glutathione; links to strength, metabolism, and inflammation rest on small studies, mostly from one research group with a financial conflict. Benefit likely depends on how depleted someone is. Generally well tolerated; broad longevity promise remains unproven. (Full Review)
| Marker | Target | Why |
|---|---|---|
| hs-CRP | < 1.0 mg/L | Systemic inflammation |
| Fasting glucose | 70–85 mg/dL | Glucose metabolism |
| Fasting insulin / HOMA-IR | Insulin < 5 µIU/mL; HOMA-IR < 1.5 | Insulin resistance |
| Hemoglobin A1c | < 5.4% | Longer-term glucose control |
| Homocysteine | < 8 µmol/L | N-acetylcysteine can shift this sulfur-pathway marker |
| Whole-blood / red-cell glutathione (reduced/oxidized ratio) | Higher reduced fraction | Direct target of the intervention |
| Blood pressure | < 120/80 mmHg | Vascular effect and hypotension safety |
| Comprehensive metabolic panel | Within normal limits | Liver, kidney, electrolyte safety |
| Complete blood count | Within normal limits | General safety screen |
| Fasting lipid panel | Optimal cardiometabolic targets | Cardiometabolic context |
Cadence: Baseline before starting, recheck at 8–12 weeks, then every 6–12 months for long-term users